Bender Robert & Associates Has $721,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Bender Robert & Associates decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% in the 4th quarter, HoldingsChannel reports. The firm owned 4,601 shares of the company’s stock after selling 100 shares during the period. Bender Robert & Associates’ holdings in Johnson & Johnson were worth $721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in JNJ. Xponance Inc. increased its position in Johnson & Johnson by 9.6% during the 4th quarter. Xponance Inc. now owns 344,420 shares of the company’s stock worth $53,984,000 after buying an additional 30,220 shares during the period. AIA Group Ltd increased its position in Johnson & Johnson by 46.9% during the 4th quarter. AIA Group Ltd now owns 6,706 shares of the company’s stock worth $1,051,000 after buying an additional 2,141 shares during the period. SFE Investment Counsel increased its position in Johnson & Johnson by 6.7% during the 4th quarter. SFE Investment Counsel now owns 19,636 shares of the company’s stock worth $3,078,000 after buying an additional 1,227 shares during the period. Ninety One SA PTY Ltd increased its position in Johnson & Johnson by 21.1% during the 4th quarter. Ninety One SA PTY Ltd now owns 65,877 shares of the company’s stock worth $10,326,000 after buying an additional 11,495 shares during the period. Finally, Ninety One UK Ltd increased its position in Johnson & Johnson by 0.3% during the 4th quarter. Ninety One UK Ltd now owns 4,436,013 shares of the company’s stock worth $695,301,000 after buying an additional 12,867 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, April 15th. Royal Bank of Canada decreased their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 17th. Raymond James raised their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, Bank of America decreased their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.86.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $148.53 on Thursday. The business’s 50-day moving average price is $155.69 and its 200-day moving average price is $155.47. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $357.92 billion, a price-to-earnings ratio of 9.26, a PEG ratio of 2.46 and a beta of 0.53. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.68 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s payout ratio is currently 29.68%.

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.